CA3003733C - Mucus penetrating particles with high molecular weight and dense coatings - Google Patents

Mucus penetrating particles with high molecular weight and dense coatings Download PDF

Info

Publication number
CA3003733C
CA3003733C CA3003733A CA3003733A CA3003733C CA 3003733 C CA3003733 C CA 3003733C CA 3003733 A CA3003733 A CA 3003733A CA 3003733 A CA3003733 A CA 3003733A CA 3003733 C CA3003733 C CA 3003733C
Authority
CA
Canada
Prior art keywords
peg
particles
poly
mucus
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003733A
Other languages
English (en)
French (fr)
Other versions
CA3003733A1 (en
Inventor
Justin Hanes
Katharina MAISEL
Laura M. Ensign
Richard Cone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3003733A1 publication Critical patent/CA3003733A1/en
Application granted granted Critical
Publication of CA3003733C publication Critical patent/CA3003733C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
CA3003733A 2015-10-30 2016-10-31 Mucus penetrating particles with high molecular weight and dense coatings Active CA3003733C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248432P 2015-10-30 2015-10-30
US62/248,432 2015-10-30
PCT/US2016/059661 WO2017075565A1 (en) 2015-10-30 2016-10-31 Mucus penetrating particles with high molecular weight and dense coatings

Publications (2)

Publication Number Publication Date
CA3003733A1 CA3003733A1 (en) 2017-05-04
CA3003733C true CA3003733C (en) 2021-04-20

Family

ID=57288512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003733A Active CA3003733C (en) 2015-10-30 2016-10-31 Mucus penetrating particles with high molecular weight and dense coatings

Country Status (8)

Country Link
US (1) US10668025B2 (cg-RX-API-DMAC10.html)
EP (1) EP3368008A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018533579A (cg-RX-API-DMAC10.html)
KR (1) KR20180075650A (cg-RX-API-DMAC10.html)
CN (1) CN108472250A (cg-RX-API-DMAC10.html)
AU (1) AU2016343840A1 (cg-RX-API-DMAC10.html)
CA (1) CA3003733C (cg-RX-API-DMAC10.html)
WO (1) WO2017075565A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
CA2859046C (en) * 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
LT3820439T (lt) 2018-09-11 2022-01-10 Lead Biotherapeutics Ltd. Mukoadhezinė dispersinė nanodalelių sistema ir jos gamybos būdas
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
JP2023529194A (ja) * 2020-06-11 2023-07-07 ヤンセン バイオテツク，インコーポレーテツド 局所薬物送達のための自己包埋粒子の制御放出
JP7842983B2 (ja) * 2021-02-25 2026-04-09 学校法人神戸学院 腸管吸収用補助剤及びその利用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
JP2010502713A (ja) * 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CA2859046C (en) * 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
US9415020B2 (en) * 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CA2872519C (en) * 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings

Also Published As

Publication number Publication date
US20180221293A1 (en) 2018-08-09
US10668025B2 (en) 2020-06-02
CN108472250A (zh) 2018-08-31
CA3003733A1 (en) 2017-05-04
JP2018533579A (ja) 2018-11-15
EP3368008A1 (en) 2018-09-05
WO2017075565A1 (en) 2017-05-04
AU2016343840A1 (en) 2018-06-07
KR20180075650A (ko) 2018-07-04

Similar Documents

Publication Publication Date Title
US10668025B2 (en) Mucus penetrating particles with high molecular weight and dense coatings
US9629813B2 (en) Nanoparticle formulations with enhanced mucosal penetration
US20210196829A1 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
Nafee et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
Seo et al. Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect
Cote et al. Nanomedicine for drug delivery throughout the alimentary canal
Wang et al. Targeted delivery of geranylgeranylacetone to mitochondria by triphenylphosphonium modified nanoparticles: a promising strategy to prevent aminoglycoside-induced hearing loss
WO2021057007A1 (zh) 一种雷帕霉素纳米缓释剂及其制备方法
Tan et al. Fabrication and characterization of clozapine nanoemulsion sol–gel for intranasal administration
Sobczyński et al. Mixed micelles as drug delivery nanocarriers
Gao et al. Oleanolic acid-loaded PLGA-TPGS nanoparticles combined with heparin sodium-loaded PLGA-TPGS nanoparticles for enhancing chemotherapy to liver cancer
CN109730966A (zh) 一种壳寡糖修饰的自携式无载体鼻腔纳米制剂脑靶向递送系统及其制备方法
Di Martino et al. Multidrug delivery system based on polysaccharide nanocomplexes for controlled delivery of a combination of chemotherapeutics
Dubey et al. Polymer-Based Carriers for Targeting Lymphatic System
Stieger et al. The use of dendrimers to optimize the physicochemical and therapeutic properties of drugs
Al-Qushawi Faculty of Veterinary Medicine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180430

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025